Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_3
4
80%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (20.0%)
Phase 34 (80.0%)

Trials by Status

terminated120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_2

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

NCT00903838
completedphase_3

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

NCT00407095
completedphase_3

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

NCT00335374
completedphase_3

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

NCT00332917
completedphase_3

SLV308 for Treatment of Patients With Early Parkinson's Disease

NCT00269516

Clinical Trials (5)

Showing 5 of 5 trials
NCT00903838Phase 2

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

Terminated
NCT00407095Phase 3

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

Completed
NCT00335374Phase 3

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Completed
NCT00332917Phase 3

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

Completed
NCT00269516Phase 3

SLV308 for Treatment of Patients With Early Parkinson's Disease

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5